help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Glasscock, G. F.
Right arrow Articles by Rosenfeld, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Glasscock, G. F.
Right arrow Articles by Rosenfeld, R. G.

Endocrinology, Vol 130, 203-210, Copyright © 1992 by Endocrine Society


ARTICLES

Effects of continuous infusion of insulin-like growth factor I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized rat

GF Glasscock, AN Hein, JA Miller, RL Hintz and RG Rosenfeld
Stanford University School of Medicine, Department of Neonatology and Pediatric Endocrinology, California 94305.

In this study, we examined the effects of systemically administered insulin-like growth factor (IGF)-I and -II on growth of the hypophysectomized (Hx) neonatal rat. Neonatal Wistar rats were Hx or sham Hx on postnatal day (PND) 6 and implanted sc with Alzet pumps on PND 10. Recombinant human IGF-I or -II were infused between PND 10 and 18 at an average dose of 1.9 micrograms/g body weight (BW) per day. In addition, some groups received daily sc injections of recombinant human GH or thyroxine (T4) at 2.5 micrograms and 25 ng/g BW per day, respectively. Pups were sacrificed on PND 18 and serum IGF levels determined. Despite restoration of serum IGF-I levels to sham control values in the Hx pups infused with IGF-I, no significant increase in BW occurred, although some increase in individual organ growth was observed (spleen, kidney, lung). Similarly, administration of IGF-II proved ineffective as a growth promoter in the neonatal Hx rat. In contrast, GH alone stimulated BW gain (P less than 0.001). T4 proved most potent in increasing skeletal growth (50% increase over Hx controls, P less than 0.001), without increasing serum IGF-I or -II levels. IGF-I and GH were equally effective in promoting a small yet statistically significant (17% over Hx controls, P less than 0.05) increase in skeletal growth. A synergistic effect on BW was observed with combined administration of T4 plus IGF-I to the Hx pups (P less than 0.05). The effects of hormonal therapy on serum IGF binding proteins (IGFBPs) was assessed by Western ligand blots. Administration of IGF-I, but not GH, resulted in increased levels of IGFBP-3, the predominant IGFBP of the adult rat. We conclude that systemically administered IGFs in doses that result in normalization of serum levels are ineffective promoters of somatic growth in neonatal rats. While normalization of serum IGF-I levels does result in modest skeletal growth, selective organ growth and increased serum IGFBP-3, growth stimulation does not equal that seen with GH (body weight) or thyroid hormone (skeletal growth). Differences in IGFBP profiles fail to account for the increased potency of GH as a promoter of BW gain. Thus, our data do not support a major endocrine role for IGF-I or -II in neonatal growth, but are consistent with an autocrine/paracrine action of IGF in the mediation of neonatal mammalian growth.


This article has been cited by other articles:


Home page
Am. J. Physiol. Cell Physiol.Home page
P. M. Yamada and K.-W. Lee
Perspectives in mammalian IGFBP-3 biology: local vs. systemic action
Am J Physiol Cell Physiol, May 1, 2009; 296(5): C954 - C976.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
Y. Kasukawa, D. J. Baylink, R. Guo, and S. Mohan
Evidence that Sensitivity to Growth Hormone (GH) Is Growth Period and Tissue Type Dependent: Studies in GH-Deficient lit/lit Mice
Endocrinology, September 1, 2003; 144(9): 3950 - 3957.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. Hoeflich, S. Nedbal, W. F. Blum, M. Erhard, H. Lahm, G. Brem, H. J. Kolb, R. Wanke, and E. Wolf
Growth Inhibition in Giant Growth Hormone Transgenic Mice by Overexpression of Insulin-Like Growth Factor-Binding Protein-2
Endocrinology, May 1, 2001; 142(5): 1889 - 1898.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
M. M. Weber, C. Fottner, P. Schmidt, K. M. H. Brodowski, K. Gittner, H. Lahm, D. Engelhardt, and E. Wolf
Postnatal Overexpression of Insulin-Like Growth Factor II in Transgenic Mice Is Associated with Adrenocortical Hyperplasia and Enhanced Steroidogenesis
Endocrinology, April 1, 1999; 140(4): 1537 - 1543.
[Abstract] [Full Text]


Home page
J. Pharmacol. Exp. Ther.Home page
S. R. Thornton and F. L. Smith
Characterization of Neonatal Rat Fentanyl Tolerance and Dependence
J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 514 - 521.
[Abstract] [Full Text]


Home page
EndocrinologyHome page
Z. S. Gucev, Y. Oh, K. M. Kelley, J. I. Labarta, P. Vorwerk, and R. G. Rosenfeld
Evidence for Insulin-Like Growth Factor (IGF)-Independent Transcriptional Regulation of IGF Binding Protein-3 by Growth Hormone in SKHEP-1 Human Hepatocarcinoma Cells
Endocrinology, April 1, 1997; 138(4): 1464 - 1470.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1992 by The Endocrine Society